|
CaMKII in LTP, Alzheimer’s disease, and beyond| title | CaMKII in LTP, Alzheimer’s disease, and beyond |
|---|
| start_date | 2026/09/14 |
|---|
| schedule | 11h30 |
|---|
| online | no |
|---|
| location_info | NC |
|---|
| summary | Ulli Bayer started working on CaMKII as a graduate student in Hamburg, Germany. He continued working on CaMKII throughout his PostDoc at Stanford and in his own lab at CU Anschutz, where he rose through the ranks to tenured full professor. In Ulli’s lab, the focus is on (i) functions in synaptic plasticity, (ii) how it goes wrong in disease, and (iii) how to fix it. The diseases of interest range from Alzheimer’s to stroke, but all involve the CaMKII interplay with the NMDA type glutamate receptor subunit GluN2B. |
|---|
| responsibles | NC |
|---|
| |
|